0000899243-19-023627.txt : 20190916 0000899243-19-023627.hdr.sgml : 20190916 20190916161520 ACCESSION NUMBER: 0000899243-19-023627 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190916 FILED AS OF DATE: 20190916 DATE AS OF CHANGE: 20190916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SULIMAN SHEHNAAZ CENTRAL INDEX KEY: 0001713070 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39035 FILM NUMBER: 191094872 MAIL ADDRESS: STREET 1: 901 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 10x Genomics, Inc. CENTRAL INDEX KEY: 0001770787 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 455614458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: (925) 401-7300 MAIL ADDRESS: STREET 1: 6230 STONERIDGE MALL ROAD CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: 10X Genomics, Inc. DATE OF NAME CHANGE: 20190315 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-16 0 0001770787 10x Genomics, Inc. TXG 0001713070 SULIMAN SHEHNAAZ C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 1 0 0 0 Stock Option (right to buy) 30.00 2019-09-16 4 J 0 100000 0.00 D 2029-08-07 Class B Common Stock 100000 0 D Stock Option (right to buy) 30.00 2019-09-16 4 J 0 100000 0.00 A 2029-08-07 Class A Common Stock 100000 100000 D Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. One forty-eighth of the shares subject to the option vested on September 7, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. /s/ Eric S. Whitaker, as Attorney-in-Fact 2019-09-16